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Purpose of the study
To assess week 12 virologic efficacy and tolerability of
tipranavir (TPV) in a cohort of French HIV-infected
patients.
Methods
Prospective cohort of French HIV-infected patients. Data
were collected from September 2003 in extended access
program and after TPV was licensed (December 2005) in
seven clinical units using Nadis electronic medical record
databases.
Summary of results
On November 1, 2007, 207 patients have been treated
with TPV: median age 44 years [40–50], 48% stage C, 81%
male, 43% MSM, 28% co-infected (72% HIV/HCV),
median HIV infection duration 15 years [12–18]. Median
nadir of CD4 cell counts was 53/mm3 [11–113], and
zenith of HIV-RNA was 5.6 log cp/mL [5–5.9].
At baseline, CD4 cell count and HIV-RNA were 153/mm3
[65–279] and 4.6 log cp/mL [3.8–5.2], respectively.
Resistance mutations testing is available in 94 patients
infected with a sub-type B virus: 71/94 patients have no
resistance to TPV according the ANRS algorithm 2008. All
the patients were ARV-experienced, with a median antiret-
roviral treatment duration of 10 years [IQR 9–12], 11 pre-
vious ARV regimens [7–15] including eight PI-including
regimens [5–11], an LPV exposure of 24 months [6–40]
and three PI-containing treatment interruption for viro-
logic failure [2–6]. TPV initiation is due to virologic failure
of the previous regimen in 75% of the cases. TPV/r was
most often combined with two NRTIs + ENF (31%). TPV/
r was associated with ENF in 63% of the patients in whom
80% were ENF-naïve.
At week 12, HIV-RNA was below 200 cp/mL in 53.5% of
patients. Median increase in CD4 cell count was 53/mm3
[5–115]. TPV/r was stopped in 69% of the patients after
median treatment duration of 66 weeks mainly for treat-
ment failure (46%) or adverse events (29%) including
hepatitis toxicity (10%) and GI disturbance (8%). Grade
3–4 hepatic cytolysis (ALAT>5 N) occurred in 13 patients
(6%).
Conclusion
In this highly treatment-experienced patient population,
more than 50% of the patients reached <200 copies/mL at
week 12; and 42 patients stopped TPV/r for adverse
events. TPV/r-containing regimens can be a valuable
option in this highly ARV-experienced population.
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